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Sirtuins are a family of proteins involved in multiple aspects of cellular function. Humans encode 
seven sirtuin homologs, which play important roles in aging, diabetes, neurodegenerative disorders, 
and cancer. However, "the biggest challenge in the field has been to determine whether modulation 
of sirtuin activity can be used for therapeutic benefit," according to Dr. Julian Simon in the Clinical 
Research and Human Biology Divisions. A new study from the laboratories of Dr. Simon and Dr. 
Antonio Bedalov (Clinical Research Division), published in the Journal of Medicinal Chemistry, 
describes the development of selective inhibitors to three of the human sirtuin isoforms and shows 
that selective inhibition of SIRT2 demonstrated anticancer activity. 
Sirtuins function as protein deacetylases, removing acetyl groups from histones and other proteins to 
regulate aging, metabolism, and development. Both human isoforms SIRT1 and SIRT2 deacetylate 
and inhibit the function of tumor suppressor proteins, including p53. Inhibiting tumor suppressor 
proteins drives cancer formation by promoting the survival of cells that have DNA damage or have 
accumulated oncogenic mutations. Previously, the Simon lab identified a relatively non-selective 
sirtuin inhibitor, cambinol, which inhibits both SIRT1 and SIRT2 isoforms by competing for substrate 
binding (Heltweg et al., 2006). Cambinol blocked lymphoma cell growth in vitro and in vivo, and 
blocked the removal of acetyl groups from the SIRT1 target p53 and the SIRT2 target α-tubulin.  
 In the current work, the Simon laboratory aimed to develop more selective sirtuin inhibitors to 
elucidate which specific sirtuin isoform is a valid anti-lymphoma drug target. The researchers used 
medicinal chemistry to determine what effect structural changes have on the desired biological 
activity of cambinol, the so-called Structure Activity Relationship or SAR. To guide the structural 
changes in the chemical compound, the researchers first mapped where the inhibitor interacted with 
the SIRT1 protein using saturation transfer difference (STD) NMR. Newly generated compounds 
were first tested using purified recombinant SIRT1, SIRT2, and SIRT3 enzymes. The researchers 
developed one compound with >7.8-fold selectivity for SIRT1 and another with >15.4-fold selectivity 
of SIRT2. A third compound was potent against SIRT3, and also inhibited SIRT1 or SIRT2 at higher 
concentrations. 
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These three inhibitors were then tested in cell-based assays with a Burkitt’s lymphoma cell line, 
looking at cell viability after drug treatment and the induction of apoptosis. The researchers found 
that inhibition of SIRT2, but not SIRT1 or SIRT3, correlates with anti-lymphoma activity (r=0.56, 
p=0.0014). The three compounds were tested for cellular cytotoxicity against a larger panel of 
lymphoma cell lines, as well as breast, colon, and lung cancer cell lines and compared to normal, 
untransformed B cell lines. The SIRT2-selective inhibitor had an inhibitory concentration killing 50% 
of cells (IC50) of 3 to 7 micromolar in the cancer cell lines compared to 22 to 28 micomolar in the 
non-transformed B-cell lines.  
 Overall, this study demonstrated sirtuin inhibitors are valid anticancer agents. According to Dr. 
Simon, "we now have a better idea of how to keep improving this compound series." Based on 
results from the STD NMR experiments, the researchers identified positions in the chemical 
compound as potential sites for improving selectivity and potency of inhibitors for the various sirtuin 
isoforms.  
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Image provided by Dr. Julian Simon 
The structures of the lead compound SM-24 (top) and the SIRT2 protein (bottom). SM-24 selectively 
inhibits SIRT2 activity and blocks lymphoma cell growth. 
 
